Policy / Regulatory

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

CompanyDrug

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

CompanyDrug

Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

CompanyDeals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

CompanyDeals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

CompanyDrug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

CompanyDeals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

CompanyDrug

Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment

CompanyDrug

Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease

CompanyDeals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements